BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 32147582)

  • 21. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
    Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
    Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
    Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
    Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activation of natural killer cells by Bacillus Calmette-Guérin.
    Brandau S; Böhle A
    Eur Urol; 2001 May; 39(5):518-24. PubMed ID: 11464031
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
    Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
    Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12.
    Morillon YM; Su Z; Schlom J; Greiner JW
    J Immunother Cancer; 2019 Jun; 7(1):150. PubMed ID: 31186063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bacillus Calmette-Guérin induces the expression of peroxisome proliferator-activated receptor gamma in bladder cancer cells.
    Lodillinsky C; Umerez MS; Jasnis MA; Casabé A; Sandes E; Eiján AM
    Int J Mol Med; 2006 Feb; 17(2):269-73. PubMed ID: 16391825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of iNOS activity enhances the anti-tumor effects of alpha-galactosylceramide in established murine cancer model.
    Ito H; Ando T; Seishima M
    Oncotarget; 2015 Dec; 6(39):41863-74. PubMed ID: 26496031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
    Hori S; Miyake M; Tatsumi Y; Morizawa Y; Nakai Y; Onishi S; Onishi K; Iida K; Gotoh D; Itami Y; Tanaka N; Fujimoto K
    Oncol Rep; 2019 Mar; 41(3):1863-1874. PubMed ID: 30628699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
    Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
    Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder.
    Nunez-Nateras R; Castle EP; Protheroe CA; Stanton ML; Ocal TI; Ferrigni EN; Ochkur SI; Jacobsen EA; Hou YX; Andrews PE; Colby TV; Lee NA; Lee JJ
    Urol Oncol; 2014 Jan; 32(1):45.e23-30. PubMed ID: 24055426
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of recombinant hIFN-alpha-2b-BCG on mouse bladder tumor MB49 cells in vitro].
    Sun EL; Fan XD; Han RF; Niu YJ
    Zhonghua Zhong Liu Za Zhi; 2010 Apr; 32(4):244-8. PubMed ID: 20510071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro.
    Liu W; O'Donnell MA; Chen X; Han R; Luo Y
    Cancer Immunol Immunother; 2009 Oct; 58(10):1647-55. PubMed ID: 19214503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of cancer stem cells in immunotherapy for bladder cancer: An in vitro study.
    Özcan Y; Çağlar F; Celik S; Demir AB; Erçetin AP; Altun Z; Aktas S
    Urol Oncol; 2020 May; 38(5):476-487. PubMed ID: 32192892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer.
    Jansson OT; Morcos E; Brundin L; Lundberg JO; Adolfsson J; Söderhäll M; Wiklund NP
    Br J Cancer; 1998 Sep; 78(5):588-92. PubMed ID: 9744496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors.
    Kamat AM; Tharakan ST; Sung B; Aggarwal BB
    Cancer Res; 2009 Dec; 69(23):8958-66. PubMed ID: 19903839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells.
    Luo Y; Han R; Evanoff DP; Chen X
    Clin Exp Immunol; 2010 Jun; 160(3):359-68. PubMed ID: 20148913
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumour immunity of Bacillus Calmette-Guerin and interferon alpha in murine bladder cancer.
    Gan YH; Zhang Y; Khoo HE; Esuvaranathan K
    Eur J Cancer; 1999 Jul; 35(7):1123-9. PubMed ID: 10533458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.
    Rentsch CA; Derré L; Dugas SG; Wetterauer C; Federer-Gsponer JR; Thalmann GN; Ingersoll MA
    Eur Urol Focus; 2018 Jul; 4(4):485-493. PubMed ID: 30415921
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.
    Domingos-Pereira S; Sathiyanadan K; Polak L; Haefliger JA; Schmittnaegel M; Ries CH; Jichlinski P; Roth B; Derré L; Nardelli-Haefliger D
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.